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ORIGINAL RESEARCH

Gait Mechanics Are Different Between Healthy Controls
and Patients With Multiple Sclerosis
Jessie M. Huisinga,1 Kendra K. Schmid,2 Mary L. Filipi,2 and Nicholas Stergiou2,3
1University

of Kansas Medical Center; 2University of Nebraska Medical Center;
3University of Nebraska at Omaha

Multiple sclerosis (MS) causes severe gait problems in relatively young individuals, yet there have been
limited studies to quantitatively identify the specific gait parameters that are affected. The purpose of this
study was to define any differences in biomechanical gait parameters between patients with MS and healthy
controls. A total of 31 MS patients and 31 healthy controls were evaluated: joint torques and joint powers
were calculated at the ankle, knee, and hip during the stance phase of gait. The self-selected walking velocity
was used as a covariate in the analysis to ensure that group differences were not due to differences in walking
velocity between the MS and healthy control groups. Reduced angular range, less joint torque, and reduced
joint power were seen in patients with MS. We also found significant correlations between biomechanical
gait parameters and EDSS score, which provides a clinical rating of disease severity. Our findings provide
a quantitative assessment of the gait mechanics employed in patients with MS. The altered lower extremity
mechanics observed in patients with MS reflect both a neurological and strength deficit compared with healthy
controls during walking.
Keywords: joint kinetics, neurological disease, gait velocity, lower extremity
Multiple sclerosis (MS) is an autoimmune disease
that causes progressive neurodegeneration and is commonly diagnosed in young adults between 20 and 40
years old.1 Symptoms vary widely within individuals
with MS, but commonly reported symptoms include
sensory disturbances, limb weakness, clumsiness, gait
ataxia, and cognitive deficits.2 There is a demonstrated
need for a mechanism to identify gait abnormalities in the
early stages of the disease, before the onset of a clinical
disability, which could provide better classification for
MS patients and for targeting more aggressive therapies.3
The disease severity and the clinical classification of
movement disability in MS patients are typically measured using the Kurtzke Disability Scale (EDSS). This
scale rates patients on a 20 point scale through a series
of functional system tests.4 While the scale provides the
clinician with a general perception of the patient’s level
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of disability, it does not provide information regarding
the quality of gait or any other associated movement
problems.
Quantitative evaluation of gait in the form of joint
mechanics may provide one solution to this problem.5
This analysis has been used extensively to characterize
gait abnormalities in different populations and to guide
treatment or to assess outcomes.6–12 Specifically, evaluation of joint torques and powers allows for the quantification of the relative contribution of muscle groups
during a movement, as well as the identification of the
specific type of muscular contraction (ie, concentric or
eccentric) that is controlling the joint motion. However,
in patients with MS, relatively few studies have used
such methodology to examine gait characteristics. Previous studies describe the ground reaction force and
joint angle patterns13 and balance control during gait
initiation in patients with MS.14 Recently, Kelleher et
al15 used kinematics, ground reaction forces and EMG
in MS patients and reported reduced gait speed, reduced
maximum hip and knee extension, ankle plantar flexion
angle and propulsive force compared with the control
group. Wurdeman and colleagues16 examined ground
reaction forces to describe differences in the frequency
component between MS patients and healthy controls.
Finally, relationships between gait mechanics and fatigue
and quality-of-life measures have been identified.17 While
these studies have successfully used biomechanical data
to begin to identify specific gait patterns in MS patients,
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evaluating joint torques and powers to investigate joint
muscular responses and their contributions can provide
fundamental understanding of the mechanics of walking in individuals with neuromuscular pathologies.
This information may allow for a better understanding
of how varying symptoms relate to gait problems, how
the progression of the disease affects gait, and to a classification of the different neuromuscular adaptations
that underlie any alterations in gait mechanics. Thus,
this study extends previous work by examining joint
torques and powers during gait that allow for specific
determination of muscular contributions and responses
at each joint. This study also uses walking velocity as a
covariate in the analysis to determine whether the gait
differences observed between the groups are influenced
by differences in walking velocity across the groups.
Finally, this study examines the relationship between the
gait parameters of MS patients and their clinically defined
EDSS scores to determine whether biomechanical gait
parameters are related to disease severity.
It was hypothesized that MS patients would exhibit
reduced joint torques and powers at the ankle, knee, and
hip compared with healthy age-matched controls. This
prediction was made based on the previously reported
spatial temporal alterations in MS patients where stride
lengths were found to be shorter and double support times
were found to be longer in MS patients.3,13,18 Such spatial
and temporal alterations are likely related to changes in
joint torques and powers of MS patients. In addition, it
was hypothesized that there would be significant correlations between gait parameters and EDSS scores
since patients with are assigned higher EDSS scores as
mobility decreases.4

Methods
Subjects
Thirty-one MS patients and 31 healthy controls participated in this study (Table 1). All procedures were
approved by the University’s Medical Center Institutional Review Board. Participants were recruited through
the University Medical Center’s Neurology clinic and

referrals from private practice neurology clinics. Control
subjects were recruited through family members of MS
subjects and advertisement in the community to match
for age and sex. Exclusion criteria for the MS subjects
included inability to give informed consent, an Expanded
Disability Status Scale (EDSS) score greater than or equal
to 6.5, completion of treatment for relapse less than 30
days before study participation, and any other neurological or vestibular disorder. MS subjects were not excluded
for taking any approved disease-modifying therapy for
MS19 but subjects taking the symptom-modifying medication Fampridine were excluded since it has been shown
to specifically affect gait.20

Data Collection Protocol
Patients were prepared for collection by wearing a
form-fitting outfit and obtaining anthropometric data.
Reflective markers were placed bilaterally according
to anatomical positions using a modified Helen Hayes
marker set.21 The initial starting point for the walking
trials was determined so that the subject could strike the
force platform, which was in the middle of the walkway,
with only one foot. During each trial, the subject walked
at self-selected pace over a 10 m walkway while threedimensional marker trajectories (EvaRT 5.0, Motion
Analysis Corp., Santa Rosa, CA, sampling at 60 Hz) and
ground reaction forces (Kistler force platform, Model
9281B11; Amherst, NY, sampling at 600 Hz) were simultaneously collected. Subjects rested for a minimum of
one minute between each trial. The process was repeated
to obtain five good walking trials with the patient’s foot
landing completely within the force plate without altering
the stride, and then the other limb was collected using
the same process. Data collection procedures for MS
patients and for healthy controls were identical. Joint
angle, torque, power variables and walking speed were
calculated for each trial and the average value across all
5 trials for each leg was used for analysis. This resulted
in one value for each variable for each leg. All subjects
walked at self-selected pace to ensure that the natural
walking pattern was captured since self-selected pace
is the most stable during walking22 and in MS patients,

Table 1 Demographic information for MS patients and healthy
controls
MS Patients (n = 31)

Healthy Controls (n = 31)

5 male, 26 female

8 male, 23 female

46.2 ± 10.6 y

42.0 ± 12.5 y

2.6 ± 0.7 (range 1.0–4.0)

—

Height (cm)

165.3 ± 6.7

170.6 ± 18.8

Mass (kg)

78.1 ± 15.8

77.2 ± 11.04

Walking Velocity (m/s)*

1.06 ± 0.21

1.21 ± 0.22

Sex (M/F)
Age
EDSS

*P < .05, significant difference in walking velocity between MS patients and healthy controls.

Gait Mechanics in Patients with MS

walking at a faster than preferred pace results in increased
metabolic cost.23 The ranges of walking speeds were
0.68–1.42 m/s for MS subjects and 0.69–1.55 m/s for
controls.

Data Analysis
A low-pass second order Butterworth digital filter with
a 7 Hz cutoff was used to smooth the marker trajectories
during postprocessing. Inverse dynamics were applied
using custom MATLAB programs to calculate the peak
flexor and extensor torques for the ankle, knee, and hip
joints in the sagittal plane based on algorithms described by
Winter.5 The joint torques and muscle powers (Tables 2–4)
were normalized to the subject’s body mass. The gait cycle
definitions and procedures followed for identifying these
parameters have been outlined in other gait studies.6,24–26

Statistical Analysis
Linear mixed effects modeling was used to evaluate
differences in mean joint angles, torques, and powers
between groups. Group, velocity, and the interaction
between group and velocity were included in the model
as fixed effects. In this way, the model allowed for identification of variables that were different as a result of
group, regardless of walking velocity differences between
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groups. Because both limbs of each subject were used
for analysis, random effects were included in the model
to account for the correlation between limbs of the same
subject. Spearman correlations were performed between
each joint angle, torque, and power variable and the MS
patient EDSS score. Spearman correlations were used
because the distribution of EDSS scores was not normal
according to the Shapiro-Wilk test (P = .027). Statistical
analyses were performed using SAS version 9.2. Statistical significance was set at α = .05.

Results
At the ankle, peak plantar flexion angle in early stance
(APF_ES) was significantly lower (F = 10.95, P = .016)
and peak plantar flexion angle at toe-off (APF_TO) was
significantly lower (F = 5.51, P = .022) in MS patients.
APF_TO significantly correlated (P < .001) with EDSS
score in MS patients. There were no significant differences between groups found in knee joint motion. However, peak knee flexion angle (KFLX) and knee range of
motion (KROM) significantly correlated (P = .001; P =
.012 respectively) with EDSS score in MS patients. At
the hip, extension (HEXT) at terminal stance, was also
significantly lower (F = 4.64, P = .034) in MS patients.
There was a significant interaction between group and

Table 2 Joint angle results between MS patients (MS) and healthy
controls (HC)
MS
Correlation
with EDSS

MS Mean (SD)

HC Mean (SD)

Paired Test
P-Value

APF_ES

–5.47 (3.62)

–6.58 (2.37)

0.016*

–0.019

ADF

12.74 (3.52)

11.28 (3.37)

0.142

–0.065

APF_TO

–13.53 (5.56)

–16.88 (4.73)

0.022*

–0.593‡

AROM

18.12 (3.94)

17.78 (3.24)

0.956

–0.077

KFLX

13.94 (5.60)

13.88 (5.67)

0.349

–0.565‡

KEXT

4.97 (4.10)

4.31 (3.84)

0.348

–0.289

KROM

9.33 (3.88)

9.79 (4.19)

0.437

–0.477‡

HFLX

25.18 (4.62)

27.35 (4.57)

0.088

–0.532‡

HEXT

–10.42 (4.53)

–11.91 (4.23)

0.034*†

–0.174

HROM

35.58 (4.91)

39.26 (3.84)

0.001*†

–0.635‡

Joint Angles (Degrees)

*P < .05, significant difference between MS and HC.
†P < .05, significant effect of walking velocity on difference.
‡P < .05, significant correlation between gait variable and EDSS score.
APF_ES—peak ankle plantar flexion angle during early stance; ADF—peak ankle dorsiflexion angle during
late stance; APF_TO—peak ankle plantar flexion angle at toe-off; AROM—total angle range of motion during
stance phase; KFLX—peak knee flexion angle during stance; KEXT—peak knee extension angle during stance;
KROM—total knee range of motion during stance phase; HFLX—peak hip flexion angle during early stance;
HEXT—peak hip extension angle during late stance; HROM—total hip range of motion during stance phase.
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Table 3 Joint torque results between MS patients (MS) and healthy
controls (HC)
MS Mean (SD)

HC Mean (SD)

P-Value

MS Correlation
with EDSS

ADT

–0.267 (0.072)

–0.381 (0.163)

0.002*

–0.296

APT

1.195 (0.141)

1.354 (0.219)

<0.001*

–0.297

KET

0.490 (0.203)

0.709 (0.236)

0.009*

–0.580‡

KFT

–0.291 (0.154)

–0.256 (0.232)

0.086

–0.013

HET

0.650 (0.207)

0.789 (0.238)

0.157

0.062

HFT

–0.765 (0.189)

–0.975 (0.277)

0.003*

0.148

Joint Torques (N·m/kg)

*P < .05, significant difference between MS and HC.
‡P < .05, significant correlation between gait variable and EDSS score.
ADT—peak ankle dorsiflexor torque during early stance; APT—peak ankle plantar flexor torque during late
stance; KFT—peak knee flexor torque during stance; KET—peak knee extensor torque during stance; HFT—
peak hip flexor torque during late stance; HET—peak hip extensor torque during early stance.

Table 4 Joint Power results between MS patients (MS) and Healthy
Controls (HC).
MS Mean (SD)

HC Mean (SD)

P-Value

MS Correlation
with EDSS (ρ)

A1

–0.398 (0.196)

–0.601 (0.261)

0.015*

–0.409‡

A2

2.440 (0.668)

3.121 (0.874)

0.008*†

–0.574‡

K1

–0.675 (0.353)

–1.021 (0.430)

0.006*

–0.595‡

K2

0.436 (0.276)

0.533 (0.308)

0.492

–0.398‡

K3

–0.511 (0.217)

–0.857 (0.594)

0.019*†

–0.173

H1

0.460 (0.238)

0.617 (0.298)

0.073

–0.104

H2

–0.651 (0.253)

–0.903 (0.366)

0.016*

–0.497‡

H3

0.495 (0.114)

0.672 (0.321)

0.014*

–0.109

Joint Powers (W/kg)

*P < .05, significant difference between MS and HC.
†P < .05, significant effect of walking velocity on difference.
‡P < .05, significant correlation between gait variable and EDSS score.
Note. Negative joint power values indicate power absorption, and positive values indicate power generation.
A1—peak ankle power absorption in early stance; A2—peak ankle power generation in late stance; K1—peak
knee power absorption in early stance; K2—peak knee power generation in midstance; K3—peak knee power
absorption in late stance; H1—peak hip power generation in early stance; H2—peak hip power absorption in
late midstance; H3—peak hip power generation in late stance.

velocity for HEXT (F = 4.35, P = .041), which showed
that at slow walking velocities HEXT was significantly
lower (t = 2.01, P = .049) in patients with MS but at faster
walking velocities, there was no difference (t = 0.79, P =
.434). Peak hip flexion (HFLX) significantly correlated
(P = .002) with EDSS score in MS patients. Total hip
range of motion (HROM) was significantly lower (F =
18.08, P < .001) in MS patients. There was a significant

interaction between group and velocity for HROM (F
= 14.25, P = .003), which showed that at slow walking
velocities HROM was significantly lower (t = 4.69, P =
.001) in patients with MS but at faster walking velocities,
there was no difference (t = 0.04, P = .967). HROM also
significantly correlated (P < .001) with EDSS score in
MS patients such that subjects with higher EDSS scores
had lower HROM.

Gait Mechanics in Patients with MS
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At the ankle, dorsiflexor torque during early stance
(ADT) and plantar flexor torque during late stance (APT)
were significantly lower (F = 10.50, P = .002; F = 13.73,
P < .001; respectively) in MS patients (Figure 1, top).
The knee extensor torque (KET) during early stance was
significantly lower (F = 7.29, P = .009) and hip flexor
torque (HFT) during late stance was significantly lower

(F = 9.35, P = .003) in MS patients (Figure 1, middle
and bottom). KET was significantly correlated (P = .001)
with EDSS score in MS patients. Importantly, none of
these joint torque differences were affected by the group
difference in walking velocity, which indicates significant
differences between groups was not because the groups
walked at different speeds (Table 3).

Figure 1 — Joint torque mean ensemble curves for the healthy
controls (identified with gray lines) and the MS patients (identified with black lines) at normal walking velocity. Significant
differences (P < .05) between groups for the parameters selected
are identified with an asterisk (*). ADT is peak ankle dorsiflexor
torque during early stance. APT is peak ankle plantar flexor
torque during late stance. KET is peak knee extensor torque
during stance. HFT is peak hip flexor torque during late stance.

Figure 2 — Joint power mean ensemble curves for the healthy
controls (identified with gray lines) and the MS patients (identified with black lines) at normal walking velocity. Significant
differences (P < .05) between groups for the parameters selected
are identified with an asterisk (*). A1 is the ankle power absorption during early stance. A2 is the ankle power generation during
late stance. K1 is the knee power absorption during early stance
and K3 during late stance. H2 is the hip power absorption at
midstance and H3 is the hip power generation during late stance.
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Figure 3 — Scatter plots to represent the significant interactions between specific joint power variables and walking velocity. The
gray lines are for the healthy control group and the black lines are for the MS patients group. The left graph illustrates interaction
(P = .03) between walking velocity and peak ankle power generation during late stance (A2); the right graph illustrates interaction
(P = .003) between walking velocity and peak knee power absorption during late stance (K3).

The ankle power absorption during early stance (A1)
and the ankle power generation during late stance (A2)
were significantly lower (F = 6.22, P = .015; F = 7.63, P
= .008; respectively) in MS patients (Figure 2, top). Both
A1 and A2 were significantly correlated (P = .022; P = .001
respectively) with EDSS score in MS patients. There was a
significant interaction between group and velocity for A2
(F = 4.88, P = .03), which showed that at lower walking
velocities, A2 was significantly lower (t = 3.64, P = .006) in
MS patients, but at faster walking velocities, the difference
between MS patients and controls was no longer significant
(t = 1.14, P = .260) (Figure 3, left). Knee power absorption
during early stance (K1) (F = 8.27, P = .006) and during
late stance (K3) (F = 5.93, P = .019) were both significantly
lower in the MS patients (Figure 2, middle). K1 and K2
(peak knee power generation during midstance) were both
significantly correlated (P < .001, P = .027 respectively)
with EDSS score in MS patients. There was a significant
interaction between group and velocity for K3 (F = 9.29, P
= .004), which showed that at slower walking velocity there
was no difference (t = 0.87, P = .391) between patients with
MS and controls but at faster walking velocities, K3 was
significantly lower (t = 4.04, P = .002) in patients with MS
(Figure 3, right). Hip power absorption at midstance (H2)
was significantly lower (F = 6.19, P = .16) and hip power
generation during late stance (H3) was significantly lower
(F = 6.58, P = .014) in MS patients (Figure 2, bottom). H2
was significantly correlated (P = .004) with EDSS score in
MS patients. None of the power differences at the hip were
affected by the walking velocity differences between the
MS patients and the controls, which indicates the significant
differences between groups was not because the groups
walked at different speeds.

Discussion
This study demonstrates that joint torques and powers
during walking in MS patients are significantly altered
compared with healthy controls when walking velocity

was considered as a covariate in the analysis and indicates
that differences between the two groups were independent
of walking velocity differences. Our results agree with
the original hypothesis that MS patients would exhibit
reduced joint torques and powers compared with controls.
In addition, there were several significant relationships
identified between gait variables and the EDSS score for
MS patients that indicate that the biomechanical gait variables are related to clinical measures of disease severity.
At the ankle, dorsiflexor torque during the loading
response (ADT) was reduced in MS patients. This could
occur if the resultant ground reaction force vector is
closer to the ankle joint center during loading.5 During
early stance, there was a reduced plantar flexion at the
beginning of single limb stance and overall significantly
reduced hip range of motion. These results indicate that
the ground reaction force vector likely remained closer to
the ankle joint during weight acceptance. Thus, patients
with MS could exhibit a gait pattern with the foot landing
on the ground in a less plantar-flexed position. Overall,
this joint position could reduce the requirement of the
ankle dorsiflexors to control the plantar flexion movement
during early stance. This is also evident by the significant
reduction in the ankle power absorption (A1) during early
stance, which reveals a decreased eccentric contraction
by the MS patients. This decreased contraction could be
the result of changes in joint geometry at or shortly after
touchdown, or it may suggest a decreased neuromuscular
ability to control the plantar flexion movement during
early stance.
Peak ankle plantar flexor torque was significantly
reduced in MS patients during terminal stance, which led
to a reduced concentric contraction of the plantar flexors
as revealed by the ankle power generation (A2) during
preswing (push-off power). While peak dorsiflexion
angle during late stance was not different, peak plantar
flexion at toe-off was significantly lower in MS patients,
so the angular distance traveled by the ankle is lower
and the amount of torque generated (APT) was reduced.

Gait Mechanics in Patients with MS

The reduction in plantar flexor torque will result in an
inability to support forward progression of the trunk and
to properly initiate the swing phase of gait.27 In addition
to supporting trunk progression and initiating the swing
phase of gait, ankle power generation has been reported as
the strongest predictor of step length in elderly subjects28
and has been found to correlate positively with gait velocity and stride length in older persons.5 Control subjects
walked faster than MS patients, but there was a significant
interaction between walking velocity and group (MS
vs. control) for ankle power generation (Figure 3, left).
This suggests that fast walking MS patients were able to
increase ankle power generation and achieve concentric
contractions at the ankle. It is possible that the evaluation of ankle power generation could reflect severity of
gait disturbance in persons with MS. Such a conclusion
is supported by the strong relationship between A2 and
EDSS score, which reflects clinically rated neurological
impairment. In addition, peak ankle torque at late stance
showed no group by velocity interaction. Because ankle
joint power was affected by walking velocity but peak
ankle torque was not, only angular velocity of the segment
changed at different walking speeds. This may indicate
that subjects able to walk faster could also increase
the angular velocity of the segment, which resulted in
increased ankle power at late stance and is a possible
indication of better segment control through muscle
firing. It seems the interaction observed is likely more
neurological in nature than muscular, but this conclusion
must be investigated further by identifying any changes
in muscle strength through dynamometer use and by
examining EMG changes during walking.
At the knee, extensor torque (KET) was significantly
reduced during early/midstance and power absorption
(K1) was reduced during early stance. During early
stance, the knee functions as a shock absorber by flexing and eccentrically absorbing power.29 The reduction
in K1 in patients with MS indicates that while peak knee
flexion angle was not different, the neural control of the
knee flexors was impaired so the eccentric control of
knee flexion was reduced. There was a strong relationship
between K1 and EDSS score for MS patients, which could
indicate that if K1 is reflective of reduced neural control
of the knee flexors, then patients with higher EDSS
scores (greater neurological impairment) have reduced
neural control of lower extremity muscles. During late
stance, the knee extensors again eccentrically control
knee flexion and absorb power. However, power absorption during late stance (K3) was significantly reduced in
MS patients. The inability to control knee flexion by the
extensor muscles may be the result of neuromuscular
control deficits in the MS patients since knee flexion and
extension angles were unchanged. During late stance,
with reduced ankle power generation there is reduced
energy transferred up the kinetic chain to the knee. With
less energy transferred up to the knee by the ankle plantar flexors, there is less power that needs to be absorbed
at the knee; thus K3 is reduced. Such an explanation is
also supported by Judge et al,28 who interpreted power
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absorption at the knee as a natural consequence of the
energy transferred between the ankle and knee.
There was a significant interaction between walking
velocity and group for K3, where in the MS group, as
walking velocity increased, K3 values did not increase
but in controls K3 did increase with velocity (Figure 3,
right). The interaction indicates a different neuromuscular
strategy for the patients with MS. Interestingly, there was
also a significant interaction between walking velocity A2
mentioned earlier. The relationship between A2 and K3
is such that if A2 increased with velocity then K3 should
also increase with walking velocity but instead, K3 did
not increase with walking velocity in the MS group. This
disagreement may be due to an inability of the MS group
to actively control (eccentric muscle contraction) knee
flexion by the knee extensor muscles as walking velocity
increases. This finding suggests that the MS patients who
were able to walk faster were still not able to increase
power absorption at the knee and achieve the necessary
eccentric contractions of the knee extensors. Therefore,
knee power absorption (K3) is equally affected regardless of the severity level, since K3 does not increase with
increasing walking velocity as it does in controls.
Hip joint motion showed reduced peak extension
angle (HEXT) and total range of motion (HROM) in
MS patients. Reduced HEXT limits the progression
of the trunk over the leg during stance and results in
significantly reduced flexion torque (HFT) during late
stance. Both HEXT and HROM during stance showed
an interaction between group and walking velocity. This
effect of velocity at the hip was not seen in joint torque or
power measures, which indicates that faster walking MS
patients have increased range of motion capability at the
hip, but could not activate the hip musculature adequately
to transition the leg into swing. In addition to decreased
strength during late stance, peak power generation (H3)
was lower in MS patients. During the push-off phase of
stance, the large burst of power generation is necessary
to accelerate the leg.29 The inability of MS patients to
generate sufficient power at the end of stance points to
an inability to adequately activate the flexor muscles of
the hip. Just after midstance, there is a period of power
absorption at the hip that signals the transition from joint
flexion into extension.29 Peak power absorption at this
point (H2) is also significantly lower in MS patients.
It appears joint motion control must be attenuated in
patients with MS since the transition from controlling the
joint motion (eccentric muscle action of the hip flexors)
to initiating the joint motion (concentric muscle action of
the hip extensors) is impeded by reduced neuromuscular
control. The moderate relationship between H2 and EDSS
score supports the idea that transitioning from controlling
to initiating joint motion is impaired in MS patients due
to neurological deficits since the EDSS score reflects
gross neurological impairment.4 This finding is also
supported by the reduced HROM, which indicates that
overall movement at the hip is limited to reduce the power
generation and absorption requirements during stance.
In studies of elderly, a decrease in ankle plantar flexor
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power generation at late stance is compensated with an
increase in hip power generation at the same point in the
stance phase.6,24,30 In MS patients this compensation does
not occur. It seems that MS patients are unable to adapt
any other compensatory strategies to overcome reduced
power at one joint by increasing power at another joint.
The slower walking velocity measured in MS
patients compared with controls may be explained by the
reduced dorsiflexor torque and accompanying reduced
power absorption at loading response and by reduced
ankle and hip power generation at terminal stance. These
variables have been shown to be the most important in
predicting performance during walking in both elderly
and Parkinson populations.6,12,31 Like MS, Parkinson’s
disease (PD) patients also have significantly reduced
ankle torque, reduced hip extension, and reduced hip
power during late stance.12,31
This study does have some limitations. This study did
not measure lower extremity spasticity or lower extremity
muscle strength. In future studies it would be of great
interest to examine how spasticity and muscle strength
are related to the gait parameters described in this article.
Because of the many factors that can affect gait in persons
with MS, this study did not include/exclude or classify
subjects based on any specific walking tendencies (ie,
drop foot or reported leg weakness). For this reason, the
MS group is mildly affected based on the mean EDSS
score only. Finally, gait variables were correlated with
the gross EDSS score only and not the specific functional
system scores. While it would be of interest to examine
the relationship between gait variables and, for example,
cerebellar and pyramidal signs, the focus of this article
is to examine the biomechanical differences in gait only.
In the future, it would be of high interest to expand these
findings by examining the relationship between gait and
related neurological deficits. Finally, torque and power
variables were normalized with respect to body mass,
but instead could have been normalized with respect to
walking speed or leg length, for example. However, this
study used walking speed as a covariate in the analysis
and because the groups showed no statistical difference in
mass or height, it is unlikely that leg length normalization
would have altered the results.
Despite limitations, this study found extensive significant differences in joint torques and powers of patients with
MS compared with healthy controls. These differences
provide a picture of the mechanical gait deficit seen in these
patients and indicate the importance of using advanced
gait analysis evaluation to classify disability in MS.
Importantly, the differences in gait kinetics between MS
patients and controls cannot be explained by differences
in walking velocity alone since velocity was controlled in
our statistical model. Thus, specific neuromuscular mechanisms independent of walking velocity were revealed for
this pathology including the inability to eccentrically
control muscle activity (power absorption by the ankle
dorsiflexors) and to concentrically generate muscle activity
(power generation by the ankle plantar flexors and the hip
flexors). The conclusion that the interactions between joint

powers and walking velocity are likely more neurological
in nature than muscular must be investigated further by
measuring changes in muscle strength and muscle firing
patterns during walking. The significant relationships
between EDSS score and gait variables in the MS patients
indicate that biomechanical gait variables are related to
clinical disability. Thus, gait analysis could be performed
in MS patients to support clinical decision making as is
the case for patients with cerebral palsy.10 Gait analysis
offers an additional tool to monitor disease status and
progression and to determine outcomes from rehabilitation
interventions and pharmacological treatment protocols.
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